Statin but not non-statin lipid-lowering drugs decrease fracture risk: A nation-wide case-control study

Calcified Tissue International

Volumn 79, Issue 1, 2006, Pages 27-36

  Rejnmark, L ^a   Vestergaard, P ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHYROID AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; COLESTYRAMINE; CORTICOSTEROID; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LOOP DIURETIC AGENT; MEVINOLIN; NICOTINIC ACID; POTASSIUM SPARING DIURETIC AGENT; PRAVASTATIN; SEDATIVE AGENT; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG USE; FEMALE; FOREARM FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATION; OSTEOPOROSIS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; SEX RATIO; SOCIOECONOMICS; SPINE FRACTURE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; BONE AND BONES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOREARM INJURIES; FRACTURES, BONE; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PRAVASTATIN; REGISTRIES; RISK FACTORS; SPINAL FRACTURES;

EID: 33746917196     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-006-0024-4     Document Type: Article

References (37)

1. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of Bone Formation in Vitro and in Rodents by Statins. Science 286:1946-1949
2. Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609-618
3. Oxlund H, Dalstra M, Andreassen TT (2001) Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299-304
4. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
5. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of Simvastatin on Bone Turnover and BMD: A 1-Year Randomized Controlled Trial in Postmenopausal Osteopenic Women. J Bone Miner Res 19:737-744
6. Schoofs MW, Sturkenboom MC, van der KM, Hofman A, Pols HA, Stricker BH (2004) HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 19:1525-1530
7. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA Reductase Inhibitors and the Risk of Fractures. JAMA 283:3205-3210
8. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients. JAMA 283:3211-3216
9. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydromethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
10. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L (2004) Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos Int 15:452-458
11. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HAP (2004) Use of Statins and Fracture: Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials. Arch Intern Med 164:146-152
12. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540
13. Ray WA, Daugherty JR, Griffin MR (2002) Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276-279
14. Pedersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921-1922
15. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855
16. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509-512
17. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD (2003) Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104
18. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516-526
19. Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398-2399
20. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46:263-268
21. Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156:1-10
22. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019-1028
23. Nielsen GL, Sorensen HT, Zhou W, Steffensen FH, Olsen J (1997) The pharmacoepidemiologic prescription database of North Jutland - a valid tool in pharmacoepidemiological research. Int J Risk Safety Med 10:203-205
24. Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug Utilization Studies: Methods and Uses. WHO Regional Publications, Copenhagen, pp 55-58
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383
26. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 56:221-229
27. Miettinen OS (1985) Theoretical epidemiology: Principles of occurrence research in medicine. Wiley & Sons, New York
28. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone mineral density in postmenopausal women. Lancet 355:2218-2219
29. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581-589
30. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. The American Journal of Medicine 110:584-587
31. Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766-770
32. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12:380-384
33. Johansen A, Evans RJ, Stone MD, Richmond PW, Lo SV, Woodhouse KW (1997) Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury 28:655-660
34. Sahlin Y (1990) Occurrence of fractures in a defined population: a 1-year study. Injury 21:158-160
35. Sanders KM, Pasco JA, Ugoni AM, Nicholson GC Seeman E, Martin TJ, Skoric B, Panahi S, Kotowicz MA (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res 13:1337-1342
36. Francis RM, Baillie SP, Chuck AJ, Crook PR, Dunn N, Fordham JN, Kelly C, Rodgers A (2004) Acute and longterm management of patients with vertebral fractures. QJM 97:63-74
37. Hoidrup S, Gronbaek M, Gottschau A, Lauritzen JB, Schroll M (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 149:993-1001